Financial results - RAYMEDICA SRL

Financial Summary - Raymedica Srl
Unique identification code: 33101907
Registration number: J12/1472/2014
Nace: 8622
Sales - Ron
186.310
Net Profit - Ron
5.577
Employee
4
The most important financial indicators for the company Raymedica Srl - Unique Identification Number 33101907: sales in 2023 was 186.310 euro, registering a net profit of 5.577 euro and having an average number of 4 employees. Firma isi desfasoara activitatea in domeniul Activitati de asistenta medicala specializata having the NACE code 8622.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Raymedica Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 2.796 5.318 40.625 41.705 60.127 58.333 81.483 126.789 137.079 186.310
Total Income - EUR 2.796 5.318 40.625 41.705 60.155 69.728 81.483 126.789 153.480 210.525
Total Expenses - EUR 8.659 10.490 15.051 18.286 30.948 29.100 39.900 70.415 126.644 202.935
Gross Profit/Loss - EUR -5.864 -5.172 25.573 23.419 29.207 40.627 41.583 56.374 26.837 7.590
Net Profit/Loss - EUR -5.944 -5.331 24.355 21.871 27.402 38.536 40.224 55.106 25.332 5.577
Employees 0 0 1 1 0 1 1 2 2 4
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 36.3%, from 137.079 euro in the year 2022, to 186.310 euro in 2023. The Net Profit decreased by -19.679 euro, from 25.332 euro in 2022, to 5.577 in the last year.

Check the financial reports for the company - Raymedica Srl

Rating financiar

Financial Rating -
Raymedica Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Raymedica Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Raymedica Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Raymedica Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Raymedica Srl - CUI 33101907

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 55 11.868 10.378 43.652 37.026 33.095 25.654 20.566 83.474 264.717
Current Assets 102 1.969 3.500 31.032 53.121 37.823 57.289 74.929 30.918 26.691
Inventories 0 0 0 0 0 0 87 0 255 1.047
Receivables 0 26 2.337 29.301 52.689 35.445 56.622 68.085 28.426 23.193
Cash 102 1.943 1.163 1.730 432 2.378 579 6.844 2.237 2.451
Shareholders Funds -5.899 -11.168 13.301 34.947 54.400 38.713 40.397 55.276 25.502 5.949
Social Capital 45 157 156 153 150 148 145 142 142 142
Debts 6.056 25.004 577 39.736 35.807 32.205 42.546 40.219 98.339 99.227
Income in Advance 0 0 0 0 0 0 0 0 0 190.707
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "8622 - 8622"
CAEN Financial Year 8622
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 26.691 euro in 2023 which includes Inventories of 1.047 euro, Receivables of 23.193 euro and cash availability of 2.451 euro.
The company's Equity was valued at 5.949 euro, while total Liabilities amounted to 99.227 euro. Equity decreased by -19.476 euro, from 25.502 euro in 2022, to 5.949 in 2023. The Debt Ratio was 33.5% in the year 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Raymedica Srl

Comments - Raymedica Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.